TRAb levels decreased at 6 but not 9 months .
At 6 months , patients on selenium supplementation were more likely than controls to show improved thyroid function ; however , the effect disappeared at 9 months .
Low selenium status is associated with increased risk of Graves ' disease ( GD ) .
While several trials have discussed the efficacy of selenium supplementation for thyroid function , in GD patients , the effectiveness of selenium intake as adjuvant therapy remains unclear .
In this systematic review and meta- analysis , we aim ed to determine the efficacy of selenium supplementation on thyroid function in GD patients .
Effects of selenium on short-term control of hyperthyroidism due to Graves’ disease treated with methimazole: results of a randomized clinical trial
Objective In spite of previous conflicting results , an adjuvant role of selenium in the treatment of Graves ’ disease ( GD ) hyperthyroidism has been proposed . To address this issue , a r and omized clinical trial was carried out aim ed at investigating whether selenium is beneficial on the short-term control of GD hyperthyroidism treated with methimazole ( MMI ) . Methods Thirty newly diagnosed hyperthyroid GD patients were r and omly assigned to treatment with : ( i ) MMI or ( ii ) MMI plus selenium . Primary outcomes were : control of hyperthyroidism and clinical and biochemical manifestations of hyperthyroidism [ heart rate , cholesterol , sex hormone-binding globulin ( SHBG ) , hyperthyroidism symptoms ] at 90 days . Results Baseline features of the two groups did not differ . Serum selenium at baseline was similar in the two groups and within the recommended range to define selenium sufficiency . Selenium increased with treatment in the MMI-selenium group and became significantly higher than in the MMI group . Serum malondialdehyde , a marker of oxidative stress , was similar in the two groups and decreased significantly with treatment , with no difference between groups . Administration of MMI was followed by a reduction of FT3 and FT4 , with no difference between groups . Heart rate , SHBG and symptoms of hyperthyroidism decreased , whereas total cholesterol increased in both groups with no difference between groups . Conclusions Our study , carried out in a selenium-sufficient cohort of GD patients , failed to show an adjuvant role of selenium in the short-term control of hyperthyroidism . However , selenium might be beneficial in patients from selenium-deficient areas , as well as in the long-term outcome of antithyroid treatment
TRAb levels decreased at 6 but not 9 months .
At 6 months , patients on selenium supplementation were more likely than controls to show improved thyroid function ; however , the effect disappeared at 9 months .
Low selenium status is associated with increased risk of Graves ' disease ( GD ) .
While several trials have discussed the efficacy of selenium supplementation for thyroid function , in GD patients , the effectiveness of selenium intake as adjuvant therapy remains unclear .
In this systematic review and meta- analysis , we aim ed to determine the efficacy of selenium supplementation on thyroid function in GD patients .